Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zanubrutinib + rituximab + methotrexate + liposomal doxorubicin + etoposide
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a multi-agent chemo-immunotherapy regimen combining the next-generation Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib with the anti-CD20 monoclonal antibody rituximab and a backbone of high-dose methotrexate, liposomal doxorubicin, and etoposide. Developed by researchers at West China Hospital, Sichuan University, this intensive regimen is designed to improve outcomes in patients with primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL). The combination leverages the high CNS penetration of zanubrutinib and methotrexate alongside the cytotoxic effects of doxorubicin and etoposide to target B-cell malignancies within the central nervous system. It is currently being evaluated in Phase 2 clinical trials for its efficacy and safety in these difficult-to-treat lymphoma subtypes.
- Other names
- ZR-MA-E regimen
02
Targets
TOP2A (DNA topoisomerase II)DHFR (Dihydrofolate reductase)CD20 (B-lymphocyte antigen CD20)BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on zanubrutinib + rituximab + methotrexate + liposomal doxorubicin + etoposide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zanubrutinib + rituximab + methotrexate + liposomal doxorubicin + etoposide.